

Special Issue

Systemic Therapy for Hepatocellular Carcinoma

Message from the Guest Editor

Hepatocellular carcinoma (HCC) is the most common primary liver cancer, also associated with poor prognosis. Novel systemic treatments for intermediate to advanced HCC, including chemotherapy, molecularly targeted therapy, immune checkpoint inhibitor immunotherapy and their combinations, have been evolving rapidly. Furthermore, the efficacies of therapeutic strategies, such as conversion therapy after systemic therapy or a recurrence prevention treatment after curative treatment, have previously been discussed. To improve patient outcomes through the use of well-timed optimal treatments, it is necessary to deepen our knowledge of each treatment and develop novel agents/regimens. This Special Issue aims to review the current literature and provide novel findings regarding systemic therapy mechanisms, biomarkers and strategies for advanced HCC.

Guest Editor

Dr. Atsushi Ono

Department of Gastroenterology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima 734-8551, Japan

Deadline for manuscript submissions

closed (30 September 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/143296

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)